Other News To Note
Wednesday, January 23, 2013
Molecular Partners AG, of Zurich, Swizterland, said results from a Phase I/II study published in the American Journal of Ophthalmology showed that MP0112, a long-acting anti-VEGF DARPin, was found to be safe in patients with diabetic macular edema and showed suppression of VEGF-A concentrations in aqueous humor after a single intraocular injection, with a pharmacokinetic half-life of about two weeks.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.